• Latest News
    • Menstrual Health
    • Reproductive Health
    • Fertility
    • Pregnancy
    • Maternal Health
    • Menopause
    • Hormonal Health
    • Mental Health
    • Gynecological Health
    • Endometriosis
    • Chronic Conditions
    • Sexual Wellness
    • Heart Disease
    • Pelvic Health
    • Bone Health
    • Cancer
  • Newsletter
  • Jobs
  • Events

Femtech Trendwatch: Women’s Health Digital Therapeutics; H1 2022 Digital Health Funding Trends & Startup Spotlight!

By Femtech Insider News, Trend Watch, Uncategorized July 18, 2022
ShareTwitterFacebookPinterest-circled
  • Latest News
    • Menstrual Health
    • Reproductive Health
    • Fertility
    • Pregnancy
    • Maternal Health
    • Menopause
    • Hormonal Health
    • Mental Health
    • Gynecological Health
    • Endometriosis
    • Chronic Conditions
    • Sexual Wellness
    • Heart Disease
    • Pelvic Health
    • Bone Health
    • Cancer
  • Newsletter
  • Jobs
  • Events

To continue reading…

Become a premium member and get unlimited access to articles, weekly analysis, free access to out webinars and more:

Subscribe

Already a subscriber? Log in here.

You May Also Like

Investment, News, Pelvic Health August 1, 2023
Pelvital Raises $2.68M for Flyte, Its FDA-Cleared Treatment for Stress Urinary Incontinence and Weakened Pelvic Floor
Cancer, Investment, News January 16, 2025
Teal Health Raises $10M to Launch At-Home Cervical Cancer Screening Device
Recent Posts
  • Iris Telehealth Launches Women’s Behavioral Health Solution For Lifestage Support   
  • Corner Health Raises $32.5M for Nurse Practitioner-Owned Primary Care Practices   
  • Juno Bio Raises $3.8M; Opens CLIA-Certified Sequencing Lab for Women’s Health
  • New Flo and Mayo Clinic Research Finds Widespread Confusion About Perimenopause Onset
  • FDA Approves Celcuity’s REVTORPYK for HR+/HER2-, PIK3CA Wild-Type Advanced Breast Cancer

About Femtech Insider

Advertise with us!

Become a Member!

Contact us

Privacy Policy // Terms of Use

Femtech Insider Ltd. © 2026. All rights reserved.